Cilostazol: New Claudication Drug
In January 1999, the U.S. Food and Drug Administration approved cilostazol (brand name: PLETAL) for the management of intermittent claudication, a condition in which pain develops in the lower legs during walking and sometimes at rest. It results from narrowing of the arteries that supply the leg muscles with blood and oxygen.
Cilostazol does not cure intermittent claudication
but rather reduces the pain so that patients can walk longer before
developing pain. In 8 studies, the average improvement in walking
distance was 28 to 100% for patients who took cilostazol as compared
with -10 to 30% for patients who took a placebo ("sugar pill").